1[3]Shinagawa N, Yura J, Mashita K, et al. Bacteriological and clinical evaluation of tazobactam/piperacillin in infectious diseases in surgical field[J]. Jpn J Antibiot,1995,48(2):346-367
2[4]Kuck N A, Jacobus N V, Petersen P J, et al. Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam,clavulanic acid,and sulbactam[J]. Antimicrob Agents Chemother,1989,33(4):1964-1969
3Sanders CC, Sanders WE. Microbial resistance to newer generation β-lactam antibiotics:clinical and laboratory implications[J]. J Infect Dis, 1985,151(3) :399--406.
4Wexler HM, Molitoris E, Finegold SM. Effect of β-lactamase inhibitors on the activities of variousβ-lactam agents against anaerobic bacteria[J]. Antimicrob Agents Chemother, 1991, 35 (6):1219-1224.
5Polk HC, Fink MP, Laverdiere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated in tra-abdominal infection[ J ]. Am Surg, 1993, 59 : 598--605.
6Kuye O, teal J, Devries VG, et al. Safety profile of piperacillir/tazobactam in pase I and Ⅲ clinical studies[J]. J Antimicrob Chemother, 1993, 31 (Suppl A) : 113--124.
7Perry CM, Markham A. Piporacillin/tazobactam: an updated review of its use in the treatment of bacterial infections[J]. Drugs,1999, 57(5) :805--843.
8Li J T, Lu Y, Hou J, et al. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate - to - severe bacterial infections: results of a randomized, controlled clinical trial[J].Clin Infect Dis, 1997, 24 (3): 498.
9Oshida T, Oono Y, Toyoda M, et al. Efficacy of sulbactam/cefoperazone in respiratory tract infections in elderly patients with underlying respiratory diseases[J]. Jpn J Antibiot, 1996, 49(7):710.
